{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:35:52Z","timestamp":1718138152826},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,28]]},"DOI":"10.7759\/cureus.26402","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:43:56Z","timestamp":1656445436000},"source":"Crossref","is-referenced-by-count":3,"title":["Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review"],"prefix":"10.7759","author":[{"given":"Ann","family":"Inouye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Prevalence of anxiety and depression among Hawaii's adults derived from HBRFSS 2006","author":"Salvail FS","year":"2007","unstructured":"Salvail FS, Smith JM. Prevalence of anxiety and depression among Hawaii's adults derived from HBRFSS 2006. 2007."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3886\/ICPSR36737.v1","article-title":"The Hawaii Personality and Health Cohort, 1959-1967: childhood personality data","author":"Edmonds G","year":"2017","unstructured":"Edmonds G, Hampson S, Goldberg LR, Digman J, Dubanoski J, Oshiro C.  The Hawaii Personality and Health Cohort, 1959-1967: childhood personality data. Inter-university Consortium for Political and Social Research, 2017. 10.3886\/ICPSR36737.v1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2017.1353383","article-title":"Trauma and PTSD in the WHO world mental health surveys","volume":"8","author":"Kessler RC","year":"2017","unstructured":"Kessler RC, Aguilar-Gaxiola S, Alonso J, et al.. Trauma and PTSD in the WHO world mental health surveys. Eur J Psychotraumatol. 2017, 8:1353383. 10.1080\/20008198.2017.1353383","journal-title":"Eur J Psychotraumatol"},{"key":"ref4","unstructured":"Letter from Senator Schatz to FDA and NIH. (2019). Accessed. 11\/16\/2021: https:\/\/psychedelicreview.com\/wp-content\/uploads\/2019\/06\/Letter-from-Senator-Schatz-to-FDA-and-NIH.pdf."},{"key":"ref5","unstructured":"Statement. MAPS responds to administration\u2019s letter about psychedelic research agenda and findings - Multidisciplinary Association for Psychedelic Studies - MAPS . (2019). Accessed: 11\/16\/2021: https:\/\/maps.org\/news\/media\/statement-maps-responds-to-administrations-letter-about-psychedelic-research-agenda-and-f...."},{"key":"ref6","unstructured":"Relating to Schedule I substances, 738, State of Hawaii Senate. (2021). Accessed. 11\/16\/2021: https:\/\/www.capitol.hawaii.gov\/session2021\/bills\/SB738_.pdf."},{"key":"ref7","unstructured":"FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic | FDA . (2019). Accessed. 11\/16\/2021: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depre...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer MC","year":"2016","unstructured":"Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016, 3:481-488. 10.1016\/S2215-0366(15)00576-3","journal-title":"Lancet Psychiatry"},{"key":"ref9","article-title":"History of MDMA","author":"Shulgin AT","year":"1989","unstructured":"Shulgin AT. History of MDMA. Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Peroutka SJ (ed): Springer Science & Business Media, 1989."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2050324518767442","article-title":"The early use of MDMA (\u2018ecstasy\u2019) in psychotherapy (1977-1985)","volume":"4","author":"Passie T","year":"2018","unstructured":"Passie T. The early use of MDMA (\u2018ecstasy\u2019) in psychotherapy (1977-1985). Drug sci., policy law . 2018, 4:10.1177\/2050324518767442","journal-title":"Drug sci., policy law"},{"key":"ref11","article-title":"Why MDMA should not have been made illegal","author":"Rosenbaum M","year":"1991","unstructured":"Rosenbaum M, Doblin R. Why MDMA should not have been made illegal. The drug legalization debate. Inciardi JA (ed):  Sage Publications, 1991. 135-146."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1074501","article-title":"Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (\"ecstasy\")","volume":"297","author":"Ricaurte GA","year":"2002","unstructured":"Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (\"ecstasy\"). Science. 2002, 297:2260-2263. 10.1126\/science.1074501","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1126\/science.301.5639.1479b","article-title":"Retraction","volume":"301","author":"Ricaurte GA","year":"2003","unstructured":"Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Retraction. Science. 2003, 301:1479. 10.1126\/science.301.5639.1479b","journal-title":"Science"},{"key":"ref14","unstructured":"Drugs of abuse, a DEA resource guide. (2020). Accessed. 11\/16\/2021: https:\/\/www.dea.gov\/sites\/default\/files\/2020-04\/Drugs%20of%20Abuse%202020-Web%20Version-508%20compliant-4-24-20_0.pdf."},{"key":"ref15","unstructured":"In the matter of MDMA scheduling, docket No 84-48, opinion and recommended ruling, findings of fact, conclusions of law and decision of administrative law judge on issues two through seven. (1986). Accessed. 11\/16\/2021: https:\/\/maps.org\/wp-content\/uploads\/1988\/11\/0077.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso JC","year":"2008","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar MA, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008, 40:225-236. 10.1080\/02791072.2008.10400637","journal-title":"J Psychoactive Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer MC","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011, 25:439-452. 10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2014.877321","article-title":"History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS)","volume":"46","author":"Emerson A","year":"2014","unstructured":"Emerson A, Pont\u00e9 L, Jerome L, Doblin R. History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). J Psychoactive Drugs. 2014, 46:27-36. 10.1080\/02791072.2014.877321","journal-title":"J Psychoactive Drugs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer MC","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, et al.. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019, 236:2735-2745. 10.1007\/s00213-019-05249-5","journal-title":"Psychopharmacology (Berl)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell JM","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, et al.. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021, 27:1025-1033. 10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome L","year":"2020","unstructured":"Jerome L, Feduccia AA, Wang JB, et al.. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020, 237:2485-2497. 10.1007\/s00213-020-05548-2","journal-title":"Psychopharmacology (Berl)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1075-9","article-title":"Oxytocin-dependent reopening of a social reward learning critical period with MDMA","volume":"569","author":"Nardou R","year":"2019","unstructured":"Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, D\u00f6len G. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019, 569:116-120. 10.1038\/s41586-019-1075-9","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0714-0","article-title":"Emotional remodeling with oxytocin durably rescues trauma-induced behavioral and neuro-morphological changes in rats: a promising treatment for PTSD","volume":"10","author":"Le Dorze C","year":"2020","unstructured":"Le Dorze C, Borreca A, Pignataro A, Ammassari-Teule M, Gisquet-Verrier P. Emotional remodeling with oxytocin durably rescues trauma-induced behavioral and neuro-morphological changes in rats: a promising treatment for PTSD. Transl Psychiatry. 2020, 10:27. 10.1038\/s41398-020-0714-0","journal-title":"Transl Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.565","article-title":"Potential psychiatric uses for MDMA","volume":"101","author":"Yazar-Klosinski BB","year":"2017","unstructured":"Yazar-Klosinski BB, Mithoefer MC. Potential psychiatric uses for MDMA. Clin Pharmacol Ther. 2017, 101:194-196. 10.1002\/cpt.565","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040187","article-title":"Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors","volume":"7","author":"van Wel JH","year":"2012","unstructured":"van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One. 2012, 7:e40187. 10.1371\/journal.pone.0040187","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1986.10472364","article-title":"Subjective reports of the effects of MDMA in a clinical setting","volume":"18","author":"Greer G","year":"1986","unstructured":"Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986, 18:319-327. 10.1080\/02791072.1986.10472364","journal-title":"J Psychoactive Drugs"},{"key":"ref27","article-title":"","author":"Mithoefer M","year":"2021","unstructured":"Mithoefer M, Mithoefer A, Jerome L, et al.. A manual for MDMA-assisted therapy in the treatment of PTSD. MAPS, 2021. https:\/\/maps.org\/research\/mdma\/mdma-research-timeline\/4887-a-manual-for-mdma-assisted-psychotherapy-in-the-treatment-...."},{"key":"ref28","article-title":"","author":"Ruse J","year":"2008","unstructured":"Ruse J, Jerome L, Mithoefer MC, Doblin R, Gibson E.  MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder. MAPS, 2008. https:\/\/maps.org\/research-archive\/mdma\/mt1_docs\/mdma_assisted_therapy_manual_11_24_08.pdf."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.03.003","article-title":"MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?","volume":"84","author":"Feduccia AA","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018, 84:221-228. 10.1016\/j.pnpbp.2018.03.003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00138","article-title":"A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy","volume":"10","author":"Sessa B","year":"2019","unstructured":"Sessa B, Higbed L, Nutt D. A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry. 2019, 10:138. 10.3389\/fpsyt.2019.00138","journal-title":"Front Psychiatry"},{"key":"ref31","article-title":"The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs","volume":"165","author":"Kalant H","year":"2001","unstructured":"Kalant H. The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs. CMAJ. 2001, 165:917-928.","journal-title":"CMAJ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli P","year":"2017","unstructured":"Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017, 31:576-588. 10.1177\/0269881117691569","journal-title":"J Psychopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)60464-4","article-title":"Development of a rational scale to assess the harm of drugs of potential misuse","volume":"369","author":"Nutt D","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007, 369:1047-1053. 10.1016\/s0140-6736(07)60464-4","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt DJ","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010, 376:1558-1565. 10.1016\/s0140-6736(10)61462-6","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/maq.12548","article-title":"MDMA is not ecstasy: the production of pharmaceutical safety through documents in clinical trials","volume":"35","author":"Hendy K","year":"2021","unstructured":"Hendy K. MDMA is not ecstasy: the production of pharmaceutical safety through documents in clinical trials. Med Anthropol Q. 2021, 35:5-24. 10.1111\/maq.12548","journal-title":"Med Anthropol Q"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/97971-methylenedioxymethamphetamine-mdma-assisted-therapy-in-hawaii-a-brief-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:18Z","timestamp":1707507498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/97971-methylenedioxymethamphetamine-mdma-assisted-therapy-in-hawaii-a-brief-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.26402","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,28]]}}}